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Abstract—A series of phenyl piperidine α-sulfone hydroxamate derivatives has been prepared 
utilizing a combination of solution-phase and resin-bound library technologies to afford 
compounds that are potent and highly selective for MMP-13, are dual sparing of MMP-1 and 
MMP-14 (MT1-MMP) and exhibit oral bioavailability in rats. 
 
The matrix metalloproteinases (MMPs) are a family of zinc-dependent enzymes that degrade 
all components of the extracellular matrix.1-2  There are at least 24 isozymes in the MMP family, 
and they are roughly classified on the basis of their substrate specificity: collagenases (MMP-1, -
8, -13 and -18), gelatinases (MMP-2, and-9), stromelysins (MMP-3, -10 and -11) and membrane-
type MMPs (MMP-14, -15, -16, -17, and -24) and others (MMP-7, -11, -12, -19, -20, -21, -22, 
and -23).  Clinical experience with the pan MMP inhibitor Marimastat has revealed a 
constellation of adverse effects collectively referred to as musculoskeletal syndrome (MSS).3  
We have hypothesized that this is predominantly a result of inhibiting both MMP-1 and MMP-
14, and that MMP inhibitors sparing these two isozymes should be devoid of MSS.4  Toward 
obtaining efficacy in mitigating damage suffered in osteoarthritic patients, it has been reported 
that MMP-13 mRNA levels are increased in osteoarthritic cartilage.5  Thus, we envisioned the 
development of a selective inhibitor of MMP-13 sparing both MMP-1 and MMP-14 as a safe 
means of treating osteoarthritis (OA) which we refer to as the dual-sparing hypothesis. 
 
Figure 1. 4-Substituted piperidine/piperazine sulfone hydroxamic acids 
 
 
 
 
 
 In the preceding paper,4 we demonstrated that the N-substituted phenyl isonipecotamide 
hydroxamic acid template 1 (Figure 1) yielded potent and selective MMP-13 inhibitors.  Figure 2 
shows a sequence comparison for a set of MMP family members focused on the S1’ loop.  There 
are differences in both amino acid identity and in length of the loop, as MMP-1, -2 and -9 are 
two residues shorter than MMP-13, -8 and -14.  Interaction of the amide N-substituents of 1 deep 
in the S1’ pocket was expected to affect isozyme selectivity across the MMP family.  In an effort 
to further investigate SAR in this region, we designed templates 2 and 3, where the distal phenyl 
group resides in approximately the same region as the amide N-substituents of 1.  To explore the 
effect of substituents on the distal aryl rings of 2 and 3, we undertook a parallel synthetic 
approach with the goal of optimizing MMP-13 potency and selectivity.  
 
Figure 2:  S1’ loop sequence variation across selected MMP family members 
 
 
 
A solid-phase parallel synthesis approach was used to create a small library of N-
arylpiperazine α-sulfone hydroxamic acid derivatives (2) from commercially available N-aryl 
piperazines 5.  Nucleophilic aromatic substitution of the previously reported polymer-bound aryl 
fluoride 44 with N-arylpiperazines was found to require a 10-fold excess of 5 and presence of 2 
equivalents of cesium carbonate in N-methylpyrrolidinone (NMP) at 100 degrees Celsius over 
night to achieve good conversions.  Acidic deprotection with trifluoroacetic acid afforded α-
sulfone hydroxamic acids 2 in good yields (Scheme 1). 
 
Scheme 1. Solid phase synthesis of N-arylpiperazine sulfone hydroxamates 2 
 
 
 
    
 Figure 
   * 
 MMP13  DPGALMFPIYTYTGKSHFML 
 MMP-8  DPGALMYPNYAFRETSNYSL 
 MMP-2  DPGALMAPIYTYT--KNFRL 
 MMP-9  VPEALMYPMYRFT--EGPPL 
 MMP-14 DPSAIMAPFYQWMDTENFVL 
 MMP-1  DIGALMYPSYTFS--GDVQL 
 
 Alternatively, a solution phase approach was developed to synthesize analogs with a basic 
amine in the α-heterocycle (8).  THP-protected hydroxymate 7 was obtained by reaction of 
carboxylic acid 6 with THP-protected hydroxylamine using the water-soluble carbodiimide 
EDC.6  Subsequent nucleophilic aromatic substitution with the requisite N-arylpiperazines 
followed by acidic deprotection afforded α-sulfone hydroxamic acids 6 in high yields. 
 
Scheme 2. Solution phase synthesis of N-arylpiperazine sulfone hydroxamic acids 8 
 
 
 
For the synthesis of 4-arylpiperidine phenyl sulfones 3, the required 4-aryl piperidines 11 were 
purchased commercially or prepared either via the Grignard route (Scheme 3) or via Suzuki 
coupling (Scheme 4).  For the Grignard route, similar to the method of Burns,7 the appropriate 
aryl Grignard was added to N-benzyl piperidine-4-one followed by dehydration with TFA in 
methylene chloride.  Reduction then gave 4-arylpiperidines 11.  Alternatively, enol triflate 12 
was reacted with the requisite arylboronic acid with a catalytic amount of 
tetrakistriphenylphosphine palladium to afford N-BOC-4-aryl tetrahydropyridine 13, following 
the procedure of Wustrow and Wise8 (Scheme 2).  Catalytic hydrogenation of 13 followed by 
removal of the N-Boc protecting group afforded 4-arylpiperidines 11.   
 
Scheme 3. Syntheses of 4-arylpiperidines via the Grignard route 
 
 
 
 
Scheme 4:  Syntheses of 4-arylpiperidines via Suzuki coupling 
  
Assembly of the N-arylpiperidine sulfone hydroxamic acids 3 was accomplished by a solution 
phase approach (Scheme 5) similar to that described above.  Carboxylic acid 146 was coupled 
with THP-protected hydroxylamine, then aromatic nucleophilic substitution with 11 followed by 
acidic deprotection afforded α-sulfone hydroxamic acids 3 in good yields. 
 
Scheme 5. Solution phase synthesis of 4-arylpiperidine sulfone hydroxamates 
 
 
 
The MMP inhibitory potency values for N-aryl piperazine α-sulfone hydroxamic acids (2 and 
8) are summarized in Table 1.  All compounds were determined to have no measurable potency 
at MMP-1 (IC50 >10,000 nM), hence selectivity for MMP-13 over MMP-1 is  >1000X in most 
cases.  The N-aryl piperazines (2a-2j and 8a-8b) exhibited mostly single-digit nanomolar 
potency for MMP-13, but most were also potent for MMP-2, resulting in only very modest 
selectivity for MMP-13 over MMP-2 with a number of compounds which were nearly 
equipotent.  N-Phenyl piperazine 2a was very potent for MMP-13 (IC50 = 1.7 nM) with a 14-fold 
selectivity versus MMP-2, and nearly 6000-fold selectivity versus MMP-14, whereas the 
corresponding α-piperidine 8a was nearly equipotent at MMP-13 and MMP-2 (IC50 = 3.3 and 
5.4 nM, respectively.)  The reduction in selectivity due to the change from X = O to X = N-
cyclopropyl was unexpected given the continuity between α-tetrahydropyran and α-piperidine 
analogs in our earlier MMP-1 sparing series,6 although this single pair does not necessarily 
constitute a trend. The ortho-fluorinated derivative 2b exhibited similar potency to the N-phenyl 
parent 2a, whereas the bulkier ortho-methyl and chloro derivatives 2c-2d dropped five-fold in 
potency for MMP-13, and the ortho-methoxy derivative 2e dropped 76-fold in potency.  The 
meta-derivatives 2f and 2g suffered a similar loss in potency for MMP-13.  On the other hand, 
para-substituted derivatives maintained high potency and selectivity for MMP-13, in particular 
para-methoxy derivative 2h with an IC50 = 0.5 nM for MMP-13, a 40-fold selectivity versus 
MMP-2, and the highest selectivity observed versus MMP-14 (>20,000).  para-Methyl and para-
trifluoromethyl derivatives 2i and 8b exhibited good potency for MMP-13 (1.9 and 2.4 nM, 
resp.) and selectivity versus MMP-14 (both >4000X), noting that 8b is an α-piperidine.  The 
more sterically demanding 2,4-dimethylphenylpiperazine 2j suffered a drop in potency at MMP-
13 (IC50 = 28.6 nM), although selectivity against MMP-2 was the highest of all N-
arylpiperazines at approximately 50X.   
 
Table 2 shows MMP inhibitory potencies of 4-aryl piperidine α-sulfone hydroxamates (3).  4-
Phenylpiperidine 3a was 3X less potent at MMP-13 than N-phenylpiperazine 2a but its potency 
for MMP-2 increased to 4.4 nM, making 3a equipotent for MMP-13 and MMP-2.  A substantial 
boost in MMP-13 selectivity was achieved by the presence of an ortho-methoxy substituent (3b).  
Potency of 3b for MMP-13 dropped 3-fold from the parent compound (3a), while MMP-2 
potency dropped 840-fold, generating a selectivity ratio of 211X.  On the other hand, para-
chloro analog 3c was found to have an increased potency relative to parent compound 3a at both 
MMP-13 and -2.  The substantial effect of ortho substitution on selectivity prompted further 
evaluation of additional ortho-substituted analogs (3d-i).  Generally, MMP-13 potencies were 
similar and reduced compared to 3a, but IC50’s for MMP-2 (and thus the MMP-2/13 selectivity 
ratio) corresponded approximately to the size of the substituent, with methoxy being optimal:  H 
< Cl, OH < CH3, CF3 < OMe, OEt, 4-F-C6H4.  The effect of an additional substituent was 
explored in an attempt to increase potency for MMP-13 while maintaining micromolar affinity 
for MMP-2.  The 1-naphthyl derivative 3j was slightly more potent than the ortho-methoxy 
analog 3b at MMP-13, but potency at MMP-2 increased 7-fold.  Other disubstituted analogs (3k-
n) showed a similar trend, except for 3n with a 2-methoxy and a 5-isopropyl substitution where 
MMP-13 potency dropped 4-fold.  Presumably the decreased affinity for MMP-13 was due to 
steric reasons.  Comparison of the MMP-2/13 selectivity for ortho-methoxy substituted N-aryl 
piperazine 2e (2.8-fold) with that of the 4-arylpiperidine analog 3b (211-fold) is noteworthy.  
Presumably, 3b adopts a conformation where the aryl group is orthogonal to the piperidine ring, 
evidenced by the substantial effect of ortho-substitution on  selectivity.  The energetic penalty 
for an N-aryl piperazine to adopt such a conformation would be high, which is likely responsible 
for the reduced potency of 2e at MMP-13 and the increased potency at MMP-2 relative to 3b. 
 
Based on the superior MMP-13 potency and dual MMP-1 and -14 sparing profiles of the p-
substituted N-aryl piperazines, additional analogs were prepared for more thorough enzyme and 
PK evaluation (Table 3).  Potent MMP-13 inhibition was observed for compounds 2l, 2m and 8c 
with IC50’s of 0.6, 1.0, 0.5 nM, respectively.  Selectivity versus other MMP family members was 
generally >>100-fold except for MMP-2 (4-20 fold) and MMP-3 (58-500 fold).  Rat PK for these 
three compounds showed low to moderate values for half-life and bioavailability. Aryl 
piperazine 8c had an acceptable BA of 20.7%, but a very short t1/2 of only 0.24h.  Aryl piperidine 
2l exhibited a modest bioavailability of 16%, but a much improved half-life of 2.59 h, which we 
attribute to the trifluoromethylphenyl moiety in P1’, which has enhanced the PK of other series as 
well.  4-Chlorophenyl piperidine 2m possessed a longer half-life but a disappointing BA of only 
7.4%.  Included for comparison is broader-spectrum, MMP-1 sparing α-sulfone SC-276.6  
Compound SC-276 lacks selectivity among MMPs, only significantly sparing MMP-1, yet this 
compound has the very high exposure in the rat that is compelling for development, consistent 
with its potent and efficacious antitumor activity.6 
 
In summary, the related series of compounds described herein have demonstrated single-digit 
to sub-nanomolar potency for MMP-13 combined with exceptional selectivity versus MMP-1 
and MMP-14 of typically >100X up to 20,000X.  Selectivities versus other MMPs when tested 
varied for MMP-3 (40-500X), MMP-8 (140-2500X) and for MMP-9 (20 to >4000X).  Selectivity 
for MMP-13 over MMP-2 ranged from equipotency to 200X, thus selectivities were somewhat 
lower relative to the related isonipecotate α-sulfone hydroxamate series.4  Rat PK for selected 
members of these series demonstrated bioavailabilities of up to 20.7% (8c) and a half lives of up 
to 2.6 h (2l) yet individual compounds lacked a compelling complete package to initiate 
development.  Undoubtedly the high molecular weights of these analogs (551 a.u. for 2m) plays 
a role given the recommendations of Lipinski although the limited number of rotatable bonds9 
favors the limited bioavailability that was observed.  We therefore turned our attention to lower 
molecular weight species, while applying our learnings about P1’ manipulations toward 
optimizing MMP-13 selectivity. 
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